Bioblast Pharma

Company Overview

Snapshot

Founded in January 2012, Bioblast Pharma operates with 1–10 employees and has raised $39.75 million across two funding rounds. The company was delisted from NASDAQ in April 2019 due to a merger, following its initial public offering in August 2014.

Business overview

Bioblast Pharma is a biotechnology company focused on developing therapeutic agents for patients suffering from rare and ultra-rare genetic diseases. The company's portfolio includes product candidates such as Cabaletta, a mutant protein-stabilizing platform for PolyA/Poly Q diseases; BBrm, a read-through platform addressing nonsense mutations; and mPRT, a mitochondrial protein replacement platform for mitochondrial protein deficiency diseases. Bioblast Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving patients and healthcare providers in markets like the United States.

Strategic signal

In March 2019, Bioblast Pharma merged with Enlivex Therapeutics, a company developing treatments for graft versus host disease. This strategic move led to Bioblast Pharma's delisting from NASDAQ in April 2019, signaling a significant corporate restructuring and a pivot in its operational trajectory.

Company Intelligence Q&A

What was a significant corporate event for Bioblast Pharma in 2019?

In March 2019, Bioblast Pharma completed its merger into Enlivex Therapeutics, which is focused on developing a treatment for graft versus host disease. This event led to Bioblast Pharma's delisting from NASDAQ in April 2019.

When did Bioblast Pharma conduct its Initial Public Offering?

Bioblast Pharma conducted an Initial Public Offering in August 2014, listing on NASDAQ.

What is Cabaletta?

Cabaletta is a mutant protein-stabilizing platform developed by Bioblast Pharma, based on a small repurposed molecule, designed to treat genetic diseases like PolyA/Poly Q, OPMD, SBMA, and SCA3.

What is the purpose of Bioblast Pharma's BBrm platform?

The BBrm platform by Bioblast Pharma is a read-through technology based on a small repurposed molecule, enabling the bypassing of genetic defects known as nonsense mutations or stop codons that hinder normal protein formation.

What is mPRT?

mPRT is a mitochondrial protein replacement platform developed by Bioblast Pharma, utilizing biological fusion proteins to address mitochondrial protein deficiency diseases by replacing missing or mutated proteins and restoring cell function.